The pandemic has left clinicians who offer anti-VEGF therapy challenged to incorporate new procedures into clinical practice amid the need to add screening strategies to reduce transmission risk. To support U.S. retinal specialists and ophthalmologists who deliver anti-VEGF therapy to patients with diabetic retinopathy, diabetic macular edema, neovascular age-related macular degeneration, and retinal vein occlusion, PlatformQ Health developed a four-part CME series on the treatment of retinal disease and the provision of anti-VEGF therapy amid COVID-19. The sessions were launched online live and remained on demand for the following year.

666 learners participated in the programs. Responses from learner polling as well as surveys administered two months after the training showed that 65% found the training made a positive impact on their clinical practice and 56% said it positively impacted patient experiences. Write-in examples demonstrated improvements in patient compliance with follow-up appointments, earlier patient screening, as well as improved ability to apply treatment options in practice. 

The outcomes were shared at the American Society of Retina Specialists 39th Annual Scientific Meeting.

Have questions about the posters or want to learn more about how PlatformQ Health is delivering impactful education to HCPs and patients? Email us at